
Article:
Taylor, JC orcid.org/0000-0002-2518-5799, Bongartz, T, Massey, J et al. (37 more authors) (2018) Genome-wide Association Study of Response to Methotrexate in Early Rheumatoid Arthritis Patients. The Pharmacogenomics Journal, 18 (4). pp. 528-538. ISSN 1470-269X

https://doi.org/10.1038/s41397-018-0025-5

Table 1. Summary of the demographics and clinical characteristics for the patients included in the analysis for Phase 1 and 2.

Study	Sample Origin	N	Age (years)		Female		RF positive		Mean Duration < 1 year	MTX Starting Dose (mg)		Baseline DAS28	
			Mean	(SD)	N	(%)	N	(%)		Min	Max	Mean	(SD)
Phase 1													
YEAR	UK	343	58.3	(13.1)	239	(70)	243	(73)	Yes	5	22.5	5.0	(1.2)
TEAR[a]	US	117	49.8	(12.0)	91	(66)	118	(86)	Yes	2.5	10	5.6	(1.0)
SWEFOT	Sweden	325	53.9	(14.0)	233	(71)	225	(69)	Yes	10	10	5.1	(0.9)
Netherlands	Netherlands	38	54.7	(12.2)	26	(68)	22	(58)	Yes	7.5	20	4.6	(1.2)
RAMS	UK	274	56.8	(14.1)	190	(69)			Yes	2.5	25	4.4	(1.2)
IDEA	UK	29	54.6	(12.0)	24	(69)	24	(71)	Yes	10	15	4.9	(1.3)
IACON	UK	128	59.5	(13.5)	91	(66)	78	(59)	Yes	5	25	4.3	(1.3)
EMPIRE	UK	22	53.1	(12.8)	17	(74)	14	(61)	Yes	10	10	4.2	(0.9)
CARDERA Trials[a]	UK	148	54.4	(12.9)	108	(67)	101	(68)	Yes	7.5	7.5	5.8	(1.1)
Phase 2a													
SERA	UK	429	58.4	(13.2)	279	(65)	169[b]	(65)	No[c]	5	30	4.8	(1.2)
Phase 2b													
AMBITION	International	85	52.5	(13.8)	69	(74)	62	(67)	No	7.5	7.5	6.0	(0.8)
MabThera Trials	International	32	49.6	(12.5)	23	(72)	29	(91)	No	7.5	7.5	5.7	(0.9)
Ocrelizumab Trials	International	60	51.7	(11.1)	42	(70)	55	(92)	No	7.5	7.5	6.0	(0.9)

Abbreviations: DAS28, disease activity score in 28 joints (3 component CRP version); RF, Rheumatoid Factor; SD, standard deviation. [a] CRP not available, DAS28 calculated using ESR. [b] Data available for 262 samples. [c] Median symptom duration 172 days.